The Egyptian Drug Authority (EDA) issued the Naming Guidelines for Human Pharmaceutical Products (Version 4, 2024) to standardize how trade names (brand names) for pharmaceutical products should be developed and assessed as part of the regulatory review process in Egypt. These guidelines aim to minimize medication errors, prevent confusion between product names, and ensure patient safety throughout prescribing, dispensing, and patient use.

Objective & Scope

The purpose of the guideline is to provide a clear set of criteria and best practices for selecting and evaluating trade names for human pharmaceutical products. It applies to all companies proposing proprietary names for products submitted for registration with the EDA.

Why Naming Matters?

The trade name is a key identifier used by healthcare professionals and patients. If names are similar in spelling or pronunciation to other products, there is an increased risk of medication errors, such as dispensing the wrong medication. The EDA’s naming criteria therefore focus on distinctiveness and clarity to protect public health.

Key Naming Criteria

Reuse of Cancelled Names
Reusing the trade name of a previously cancelled product is discouraged because healthcare professionals may still associate the name with the original product, leading to confusion. EDA evaluates such requests on a case-by-case basis.
Best Practices & Assessment Approach
During assessment, EDA considers the likelihood of medication errors due to similarity with other names, including orthographic and phonetic factors.
Names implying exaggerated claims (e.g., “cure”) or safety/efficacy messages beyond approved labeling are considered misleading.
Companies are encouraged to screen trade names using EDA’s tools prior to submission to reduce the likelihood of rejection.

Conclusion

The EDA Naming Guidelines (Version 4.0) offer a transparent, structured framework for evaluating pharmaceutical trade names in Egypt. By emphasizing distinctiveness, clarity, and safety, the guidelines support regulatory decision-making and help reduce risks tied to name-related medication errors.

Safety Concerns

Proposed trade names must avoid similarity to existing proprietary names in spelling or pronunciation.
Trademark registration alone is not considered sufficient justification for name acceptance.
EDA independently evaluates proposed names, even if applicants submit screening data.

Phonetic and Orthographic Distinctiveness

Names should be distinct in both how they sound and how they are written.
The EDA uses the EDA Naming Checker Tool to quantitatively assess similarity scores between proposed and existing names. Higher similarity may indicate increased risk of confusion.

Avoid Misleading Elements

Inclusion of active or inactive ingredient names (especially partial names) in the trade name can mislead end users into assuming product composition incorrectly.
Avoid using INN (International Non-Proprietary Names) stems or USAN (United States Adopted Names) stems in misleading positions that imply properties not present in the product.

Family Branding & Modifiers

EDA defines family branding as using a common root name across multiple products.
Family trade names should include modifiers that clearly differentiate products (e.g., strength, formulation). Modifiers must not be confusing or misleading, and should be meaningful and standardized where possible.

Avoid Confusing Characters

Trade names composed of unpronounceable combinations of letters or numbers (e.g., random alphanumeric strings) should generally be avoided, as they can be misinterpreted or confused with dose information.
Avoid using medical abbreviations or symbols commonly used in prescribing communication unless they are placed and designed in a way that does not introduce risk.